Sort   by:  
 Page size 
UnknownHepatocellular carcinoma: Will novel targeted drugs really impact the next future?
Not available
S-EPMC4945973 | biostudies-literature
UnknownTarlatamab: a potential new option for recurrent small cell lung cancer.
Not available
S-EPMC10413042 | biostudies-literature
UnknownKRAS as a druggable target in NSCLC: Rising like a phoenix after decades of development failures.
Not available
S-EPMC7448574 | biostudies-literature
UnknownOncogenic alterations in advanced NSCLC: a molecular super-highway.
Not available
S-EPMC10863183 | biostudies-literature
UnknownAssociation of Industry and Academic Sponsorship With Negative Phase 3 Oncology Trials and Reported Outcomes on Participant Survival: A Pooled Analysis.
Not available
S-EPMC6512293 | biostudies-literature
UnknownTreatment patterns, testing practices, and outcomes in the pre-FLAURA era for patients with EGFR mutation-positive advanced NSCLC: a retrospective chart review (REFLECT).
Not available
S-EPMC8842149 | biostudies-literature
UnknownFrom expert recommendations to multidisciplinary team decisions: a way to set out the novel perioperative options for patients with non-small-cell lung cancer.
Not available
S-EPMC9359950 | biostudies-literature
UnknownImmune checkpoint inhibitor-induced aseptic meningitis and encephalitis: a case-series and narrative review.
Not available
S-EPMC8010823 | biostudies-literature
UnknownNeoadjuvant Immunotherapy: A Promising New Standard of Care.
Not available
S-EPMC10380420 | biostudies-literature
UnknownSafety of extended interval dosing immune checkpoint inhibitors: a multicenter cohort study.
Not available
S-EPMC10323889 | biostudies-literature
Sort   by:  
 Page size